Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy …
WEBJun 20, 2024 · The results demonstrated superiority of twice-yearly lenacapavir over bHIV (primary endpoint, incidence 2.41 per 100 person-years) and superiority of twice-yearly lenacapavir over once-daily Truvada (secondary endpoint), with p<0.0001 for …
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV ...
WEBSep 12, 2024 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. Lenacapavir reduced HIV infections by 96% compared to background HIV incidence (bHIV).
Gilead’s lenacapavir: HIV prospects strongest in long-acting …
WEB4 days ago · Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...
Press Releases | Gilead
WEBJul 25, 2024 · Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA. June 05, 2024. Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis. June 04, 2024.
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy …
WEBJun 20, 2024 · Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV...
Full Efficacy and Safety Results for Gilead Investigational Twice ...
WEBFOSTER CITY, Calif., July 24, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced full efficacy and safety results from its pivotal, Phase 3 PURPOSE 1 trial.
Gilead PrEP lenacapavir succeeds in Phase 3 trial - CNBC
WEBJun 20, 2024 · Key Points. Gilead's twice-yearly medicine to prevent HIV succeeded in a Phase 3 trial. None of the roughly 2,000 women in the trial who received the lenacapavir shot contracted HIV. Gilead needs ...
Gilead's long-acting HIV drug superior to daily pill Truvada in study
WEBJune 20 (Reuters) - Gilead Sciences (GILD.O) said on Thursday a late-stage study showed its long-acting injectable drug was more effective in preventing HIV infection in women compared to its...
Newsroom | Gilead
WEBRecent Press Releases. September 10, 2024. Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies. September 05, 2024. Gilead to Present New Trodelvy® Data at the IASLC …
Gilead’s HIV prevention treatment found 100% effective in late …
WEBJun 20, 2024 · Gilead Sciences Inc.’s stock GILD jumped 4.5% early Thursday after the company said its experimental twice-yearly injection for HIV prevention was found 100% effective in a late-stage trial.
Skip to content